再鼎医药
ZLAB
23.19
-0.32
-1.36%
再鼎医药
US · ZLAB
#2554 按市值排名
上市于 2017
23.19
-0.32
-1.36%
实时 - 追踪5344个代码 - 心跳于503秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期（2026/Q3）披露持股的机构数量减少了2家。
- 机构持股总比例上升了0.9个百分点。
机构持股
- 机构持股比例
- 78.50% +0.89pp
- 机构数量
- 192 -2
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund36.50%
VC/PE Fund16.59%
Hedge Fund15.48%
Public Company6.46%
Sovereign Wealth Fund2.65%
Individual/Insider2.18%
Private Company0.83%
Other19.33%
主要股东 截至 2026-06-30
RTW Investments, LP
5.86% · 6.57M 股
TCG Crossover Management, LLC
5.47% · 6.14M 股
Baillie Gifford
5.27% · 5.92M 股
FMR
4.63% · 5.20M 股
Qiming Weichuang Venture Capital Management (Shanghai) Company Limited
4.35% · 4.89M 股
RA Capital Management, L.P.
4.21% · 4.72M 股
Vanguard Capital Management, LLC
3.89% · 4.36M 股
The Goldman Sachs Group, Inc.
3.27% · 3.67M 股
ADAR1 Capital Management, LLC
3.00% · 3.37M 股
China Universal Asset Management Company Ltd.
2.90% · 3.26M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 20次买入 · 30次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Ying Du | Founder, Chairperson & CEO | 1.09% |
| Peter Karl Wirth | Independent Director | 0.37% |
| John David Diekman | Lead Independent Director | 0.11% |
| Joshua L. Smiley | President | 0.10% |
| Wing Yu Leung | Independent Director | 0.09% |
| Leon Moulder | Independent Director | 0.08% |
| Richard Brian Gaynor | Independent Director | 0.07% |
| Michel Vounatsos | Independent Director | 0.06% |
| Rafael G. Amado | President and Head of Global Oncology Research & Development | 0.05% |
| Scott William Morrison | Independent Director | 0.05% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-30 | Yajing Chen | Chief Financial Officer | Derivative Exercise and Sale | -315 | $25.50 |
| 2026-09-30 | Yajing Chen | Chief Financial Officer | Derivative Exercise and Retained | +605 | -- |
| 2026-08-19 | Joshua L. Smiley | President | Intent to Sell (Form 144) | -98,653 | $26.18 |
| 2026-08-18 | Yajing Chen | Chief Financial Officer | Automatic Disposition | -260 | $27.00 |
| 2026-08-13 | Yajing Chen | Chief Financial Officer | Derivative Exercise and Sale | -427 | $25.90 |
| 2026-08-13 | Yajing Chen | Chief Financial Officer | Derivative Exercise and Retained | +823 | -- |
| 2026-08-11 | William David Lis | Independent Director | Automatic Disposition | -8,506 | $25.00 |
| 2026-08-10 | Yajing Chen | Chief Financial Officer | Automatic Disposition | -619 | $25.00 |
| 2026-07-01 | Ying Du | Founder, Chairperson & CEO | Derivative Exercise and Sale | -11,431 | $19.12–19.15 |
| 2026-07-01 | Ying Du | Founder, Chairperson & CEO | Derivative Exercise and Retained | +17,617 | -- |
| 2026-07-01 | Ying Du | Founder, Chairperson & CEO | Other Derivative Acquisition | +80,393 | -- |
| 2026-06-30 | Richard Brian Gaynor | Independent Director | Automatic Acquisition | +1,736 | $19.05 |
| 2026-06-29 | Ying Du | Founder, Chairperson & CEO | Derivative Exercise and Sale | -7,026 | $18.53 |
| 2026-06-28 | Ying Du | Founder, Chairperson & CEO | Derivative Exercise and Retained | +10,944 | -- |
| 2026-06-25 | Ying Du | Founder, Chairperson & CEO | Derivative Exercise and Sale | -24,543 | $17.46 |
| 2026-06-25 | Ying Du | Founder, Chairperson & CEO | Intent to Sell (Form 144) | -24,543 | $17.46 |
| 2026-06-25 | Frazor Titus Edmondson | Chief Legal Officer | Derivative Exercise and Sale | -4,103 | $17.46 |
| 2026-06-25 | Frazor Titus Edmondson | Chief Legal Officer | Intent to Sell (Form 144) | -4,103 | $17.46 |
| 2026-06-25 | Yajing Chen | Chief Financial Officer | Derivative Exercise and Sale | -2,264 | $17.46 |
| 2026-06-25 | Yajing Chen | Chief Financial Officer | Intent to Sell (Form 144) | -2,264 | $17.46 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
再鼎医药 讨论区 0 条评论